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Abstract: Acute leukaemia manifests itself into two different types being Acute Lymphocytic Leukaemia (ALL)
and Acute Myelogenous Leukaemia (AML) depending on the type of leukocyte being affected. ALL raises a
lot of concern since it is the most common type of leukaemia found in children while CML is the most common
type of leukaemia in the United States. This study shows the epidemiology, the etiology, such as chromosomal
aberrations and gene mutations and the clinical presentations consisting of both signs and symptoms. It also
includes how these types of leukaemia are diagnosed as well as their pathophysiology which comprises
detailed description of the alterations in various cellular mechanisms. Finally, the treatment involving both
chemotherapy and stem cell therapy, amongst others, has also been discussed.
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INTRODUCTION of acute leukaemia in children and 20% of acute leukaemia
By definition, leukaemia is ‘a progressive, malignant In most cases, the cause is unknown. But studies
disease of the blood-forming organs, characterised by have shown that there is possible genetic predisposition
distorted  proliferation  and development of leukocytes and this was observed among monozygotic and dizygotic
and their precursors in the blood and bone marrow’ twins of patients with ALL which showed higher
(Burgun et al., 2005). incidence  of  ALL.  Patients  with  trisomy  21 and
The most common types of acute leukaemia are: inherited diseases with excessive chromosomal fragility
C Acute Lymphocytic Leukaemia (Acute ALL. 
Lymphoblastic Leukaemia). In pediatric leukaemia most chromosome
C Acute Myelogenous Leukaemia (Acute Myeloid translocations associated with leukaemia occur in utero
Leukaemia). during fetal hematopoeisis with secondary genetic events
The term acute denotes the progression of the There were also associations of human T-cell
disease  where  there  is  a sudden and uncontrolled lymphotropic virus type 1 with adult T-cell leukaemia,
growth  of  immature  hemapoeitic  cells  at   the  expense Epstein-Barr virus with mature B-cell ALL and Human
of  normal  marrow  function.  It  is  fatal if left untreated Immunodeficiency Virus (HIV) with lymphoproliferative
but it is potentially curable with appropriate therapy disorders (Jabbour et al., 2005).
(Burgun et al., 2005). Symptoms include fatigue, lack of energy, easy
The types of leukaemia are also categorised bruising or oblivious bleeding, dyspnea, dizziness and
according to the type of leukocyte being affected. In infections.  Central  nervous  system  involvement was
lymphocytic leukaemia, malignant lymphoid cells are also observed in some subtypes and lypmhadenopathy
observed while abnormalities in myeloid cells are found in and  hepatosplenomegaly  are  noted in 20% of the
myelogenous leukaemia. patients with higher incidence in patients with T-cell ALL
ACUTE LYMPHOCYTIC LEUKAEMIA (ALL) observed (Dale et al., 2004).
ALL has an overall incidence of 1 to 1.5 per 100,000 as well as various chromosomal mutations including
persons and is particulary  common  in   children   aged  4 hyperdiploidy,  hypodiploidy  and  pseudodiploidy.  The
to  5   years with  the  incidence  shooting  to 4 to 5 per latter consists of various chromosomal translocations and
100,000 persons and in people aged about 50 with an deletions. Figure 1 summarises the cytogenetic-molecular
incidence of 2 per 100,000 persons. ALL represents 80% abnormalities in ALL (Jabbour et al., 2005).
in adults (Jabbour et al., 2005).
such as Fanconi anaemia have a higher risk of developing
occurring postnatally. 
(Jabbour et al., 2005). Elevated LDH and uric acid are also
A blast count of 20% or greater is observed in ALL
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Fig. 1: The cytogenetic-molecular abnormalities in ALL (Jabbour et al., 2005)
The World Health Organization proposed an regulatory elements within the c-myc gene. A clear
identification method based upon the immunophenotypes
as illustrated in Fig. 2. Three broad groups can be
distinguished: 
C Pre-B-cell ALL (80% approximate frequency).
C Mature B-cell ALL (<5% approximate frequency).
C T-cell  ALL  (10-15%  approximate frequency)
(Jabbour et al., 2005).
To add to the previous figure, the pre-B-cell ALL is
also positive for TdT (Terminal deoxynucleotidyl
Transferase) and HLA-dr antigens while the B-cell mature
ALL cells are negative for TdT and exhibit surface Ig
(Dale et al., 2004).
B-cell ALL: The major causes behind B-cell malignancy
are a series of chromosomal translocations effecting the
c-myc gene overexpression as shown in Fig. 3.
Other causes include mutations in p53, methylation
of Death-Associated Protein kinase (DAP-kinase) and
down-regulation of p16INK4a or p15INK4b via gene
hypermethylation impairing cell apoptosis. Besides this,
there  are  also  deletions or mutations or several negative
example  is  the  mutation  in  the  threonine  58  residue of
c-myc causing its accumulation and therefore,
overexpression as a result of impaired proteasome-
mediated degradation (Blum et al., 2004).
C-Myc overexpression causes both the activation of
certain genes involved in cell cycle progression being the
cyclins D1 and D2 and the CDKs 4 and 6 genes and the
repression of genes involved in cell cycle arrest such as
those coding for the CKIs p21  and p27. Overall, thiscip1
leads to the proliferation of B-cells.
Apoptosis is also the target of c-myc overexpression
which led to the induction of p19, increased p53,
activation of FAS, upregulation of the Bax protein and
activation of the apoptosis gene TRAP1 which codes for
a Tumour necrosis factor receptor.
Cell adhesion was also effected due to the
downregulation of collagen production and decreased
fibronectin which is mediated by c-myc over expression as
well (Blum et al., 2004).
T-cell ALL: A stepwise alteration of at least four specific
pathways is required before T-cells become fully
malignant associated with four different classes of
mutations:
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Fig. 2: Immunophenotypic classification of ALL- Different maturation stages have been identified in pre-B-cell ALL
being pre-pre B-cell ALL, common ALL and pre B-cell ALL each of which has different markers (Jabbour et al.,
2005)
Translocation Gene juxtaposition Phenotype
T(8;14)* Combination of c-myc gene with IgH enhancer Increased c-myc mRNA and protein production
T(2;8)(p12;q24) c-myc gene placed adjacent to 8 light chain locus c-myc transcription uncontrollably enhanced due to high activity
 and enhancer elements of heavy and light chains in B-cells
t(8;22)(q24;q11) c-myc gene juxtaposed to the 8 light chain c-myc transcription uncontrollably enhanced due to high activity
locus and enhancer elements of heavy and light chains in B-cells
*Different breakpoints have been identified on chromosome 8 and 14 leading to clinical variants of the disease. In for example Burkitt’s Lymphoma (BL) which
is considered as a type of B-cell acute lymphocytic leukaemia, different chromosomal breakpoints yield the endemic variant and the sporadic variant
Fig. 3: Chromosomal translocations leading to c-myc overexpression (Blum et al., 2004)
C Mutations that affect the cell cycle. important transcription factor genes. This leads to the
C Mutations that impair differentiation. obvious deregulation of transcription factors which may
C Mutations that provide proliferative and survival alter the gene expression programs that regulate
advantage. hematopoeitic differentiation of a multipotent progenitor.
C Mutations providing self-renewal capacity (De Figure 4 summarises the mutations occurring in T-cell
Keersmaecker et al., 2005). ALL and their effect on the phenotype (De Keersmaecker
The major mutation affecting the cell cycle is the Mutations in LCK, ABL1, RAS and PTEN provide
inactivation of CDKN2A and CDKN2B. These are 2 genes proliferative and survival advantage. The latter four genes
located in close proximity on chromosome region 9p21. are all involved in the T-cell receptor signalling pathway
CDKN2A encodes both p16 and p14 which are potent which is activated by the antigen binding to the MHC
regulators of the cell cycle since p16 inhibits Rb1 protein on t-cell surface. The final outcome of such TCR
phosphorylation whereas p14 activates p53. In ALL, signalling pathway is the production of IL-2 involved in
various deletions are observed in CDKN2A which T-cell proliferation. The mutations associated with
deletions vary in size and can cover large genomic proliferative and survival advantage are summarised in
regions. As a result, nearby genes such as CDKN2B Fig. 5.
(encoding p15) are therefore co-deleted. Such deletions in
CDKN2A  and  CDKN2B  are  present  in  65  and 23% of Specific treatment: Imatinib mesylate is given to ALL
T-ALL cases, respectively. Inactivation of CDKN2A and patients with ABL-1 fusions since this drug is a selective
CDKN2B can also be as a result of promoter inhibitor of the ABL-1 kinase activity (Jabbour et al.,
hypermethylation.  RB1,  p53,  p27  are  rarely  mutated in 2005).
T-ALL (De Keersmaecker et al., 2005). In the case of patients with hyperactive LCK, SRC
Mutations which impair differentiation cause the kinase inhibitors and dual SRC/ABL kinase could be used
deregulated expression of normal transcription factor (De Keersmaecker et al., 2005).
proteins. The mutations include the juxtaposition of Mutations providing self-renewal properties are
promoter and enhancer elements of T-cell receptor genes found in NOTCH1 which is involved in the regulation of
TRA@ (14q11), TRB@ (7q34-35), TRG@ (7p15) and stem cell maintenance. Its mutation occurs in a way that
TRD@ (14q11) to a small number of developmentally it provides the leukemic cells with self-renewal capacity.
et al., 2005). 
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Mutation Gene juxtaposition Phenotype
t(10;14)(q24;q11) Overexpression of HOX11-immortalise murine
haematopoietic progenitors
t(7;10)(q35;q24) Same as above
t(5;14) (q35;q32) Combination of TLX3 to the distal region of BCL11B Overexpression of TLX3 which act through oncogenes such
(a gene highly expressed in T-cell differentiation) as NOTCH 1
inv(7)(p15q34) TRB@ locus to part of HOXA@ cluster (7p15) Deregulated expression of HOXA10 and HOXA 11 causing
incomplete differentiation of T-cells
t(7;19)(q35;p13) LYL 1 juxtaposed to the TRB@ locus Overexpression of LYL 1 gene – its oncogenic potential
not yet demonstrated
t(1;14)(p32;q11) TAL1 combined with regulatory TCR gene elements Overexpression of TAL1 causes maturation arrest of T-cells
in the late cortical stage
T(7;9)(q34;q32) TAL 2 gene juxtaposed to the TRB@ locus Same as above
t(11;14)(p15;q11) Juxtaposition of LMO1 or LMO2 to the TRA@ or 
t(11;14)(p13;q11) TRD@ loci Coexpressed with TAL1
t(9;11) MLL gene rearrangement Differentiation arrest at an early T-cell differentiation
Fig. 4: Summary of the mutations in T-cell ALL affecting cell differentiation, the gene juxtaposition associated with them
and their effect on the phenotype. LYL1, TAL1 and TAL2 are members of the basic Helix Loop Helix (bHLH) family
of transcription factors which interact with DNA (De Keersmaecker et al., 2005)
Mutation Phenotype
NUP214-ABL1 fusion
ETV6-ABL1 fusion Associated with TLX1 or TLX3 expression and deletion of CDKN2A
EML1-ABL1 fusion resulting in excessive activation of survival and proliferation pathways
t(1;7)(p34;q34)-Juxtaposition of the LCK and TRB@ loci Overexpression of LCK leads to cell proliferation
RAS mutation Associated with proliferation in T-cell ALL
PTEN Inactivation Inactivation of this tumour suppressor protein leads to high concentrations
of PI3K and therefore uncontrolled proliferation
Fig. 5: Mutations providing proliferative and survival advantage (De Keersmaecker et al., 2005)
Its hyperactivity occurs due to fusion with the T-cell The first phase consists of a combination of
receptor b gene in t (7; 9) (q 34; q 34.3). corticosteroids, vincristine and anthracylines which
NOTCH1 (ICN) translocates to the nucleus where it results in complete remission rates of 72-92%. Additional
associates with other proteins to form a transcription drugs are utilised for specific ALL subtypes in order to
activator complex. ICN normally has a short half-life, being make the treatment more effective. In mature B-cell ALL,
subject to ubiquitination and degradation. In some fractionated doses of cyclophosphamide, rituximab and
mutated  forms,  the heterodimerization domain (the high-dose methotrexate are administered while in T-cell
domain joining the extracellular domain (NEC) to the ALL, cytarabine and cyclophosphamide are given.
transmembrane domain (NTM) of the NOTCH1 receptor in Studies have shown that a faster recovery has been
a covalent manner) is altered and thus destabilizing the experienced in those patients who received G-CSF
NEC and NTM intersubunit association. This leads to (Granulocyte-Colony Stimulating Factor). In fact a
increased ICN production rates without ligand remarkable faster recovery of neutrophils and platelets
stimulation. In other mutated forms PEST domain was observed compared with patients who were put on
mutations  were  observed  which  extend  the half-life of placebo (Jabbour et al., 2005).
the  ICN-containing  transcriptional  activation  complex The second phase consists of a repetition of a
(De Keersmaecker et al., 2005). modified induction schedule or stem cell transplantation.
GENERAL TREATMENT FOR ALL dose methotrexate in standard-risk B-cell lineage ALL,
Nowadays, 80% of children with ALL are cured dose  methatrexate  and  high dose cytaribine in high-risk
showing the success of this anti cancer treatment. It is B-cell lineage ALL (Jabbour et al., 2005).
divided into four phases being: The third phase includes daily 6-mercaptopurine,
C Induction. and  prednisone  given  for  2  to  3  years.  This  phase
C Intensified consolidation. does  not  include  the  B-cell  ALL  subtype  since the
C Maintenance. latter  responds  well  to  short-term dose-intense
C Central Nervous System (CNS) Prophylaxis. regimens. 
Treatment is given according to the ALL subtype-high
cyclophosphamide and cytaribine in T-cell lineage, high
weekly methotrexate and monthly pulses of vincristine
Int. J. Mol. Med. Adv. Sci., 3 (4): 138-144, 2007
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Fig. 6: The classification of Acute Myeloid Leukaemia according to the World Health Organization (Estey et al., 2006)
The fourth and last phase targets leukaemia in the neutrophils, monocytes and platelets (Jabbour et al.,
CNS. To progress to this treatment phase, there must be 2006). These AML blasts also inhibit the differentiation of
more than 5 white blood cells per microlitre in the the normal blasts into mature progeny by producing
cerebrospinal fluid and the presence of lymphoblasts. various chemokines (Estey et al., 2006).
Treatment consists on intrathecal chemotherapy with Acute Myelogenous Leukaemia is further subdivided
methotrexate, cytaribine and corticosteroids and the usual into subtypes. This classification has been proposed by
high dose systemic chemotherapy (Jabbour et al., 2005). the World Health Organisation as illustrated in Fig. 6.
ACUTE MYELOGENOUS LEUKAEMIA States with its frequency ranging between 3.8-17.9 cases
Acute Myelogenous Leukaemia (AML), also known (Jabbour et al., 2006; Estey et al., 2006).
as non-lymphocytic leukaemia, is a heterogeneous clonal AML is associated with exposure to ionising
disorder of the haematopoietic cells which have lost the radiation, benzene and to cytotoxic chemotherapy.
ability to differentiate and to respond to normal progenitor Benzene exposure is due to cigarette smoking which
regulators. The genetic reprogramming of AML blasts causes aberrations of chromosomes 5 and 7, trisomy of
makes them ineffective at generating mature red cells, chromosome  8  and  a   balanced   translocation  between
It is the most common type of leukaemia in the United
per 100,000 individuals with a ratio of 3 males: 2 females
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Fig. 7: The common chromosomal aberrations in AML (Estey et al., 2006)
Result Diagnosis
>/= 3% stain positive for myeloperoxidase or Sudan Black B Acute myeloid leukaemia
Peroxidase negative but stain for butyrate Acute monocytic leukaemia
None of the above Lineage determination based upon blasts expressing surface antigens associated with myeloid
(equivalently monocytic, erythroid, or megakaryocytic) or lymphoid immunophenotype
Fig. 8: Using cytochemical stains to determine the type of AML (Jabbour et al., 2006)
chromosomes 8 and 21 while cytotoxic chemotherapy leukocyte aggregation and clumping). There can also be
leads  to  aberrations  of  chromosomes  5  and  7 (Jabbour organomegaly, lymphadenopathy, retinal hemorrhages
et al., 2006; Estey et al., 2006). Figure 7 depicts the and organ infiltration such as the skin, the lung and brain,
common chromosomal aberrations in AML. with the latter two becoming more likely as the white-
CLINICAL PRESENTATION AND DIAGNOSIS An increase in the number of myeloblasts in the
The  patient presents with fatigue, bruising, bleeding, and there must be the presence of a minimum of 20%
fever  and  infection  which  might be fatal (Lancet) and blasts in the marrow sample. But the following mutations
this  is  due  to bone marrow failure (Estey et al., 2006). should immediately be attributed to AML irrespective
Ten  percent  of  AML  patients  present with White from the myeloblast percentage results. These mutations
Blood Cell (WBC) counts greater than 100×l0 /L and these are the cytogenetic abnormalities t(8;21)(q22;q22),9
are at a higher  risk  of tumor lysis syndrome, CNS inversion (16)(pl3q22) or t(16;16)(pl3;q22) and t(15;17)
involvement and leukostasis (Abnormal intravascular (q22;ql2) (Jabbour et al., 2006).
blood-cell count rises above 50 000 (Jabbour et al., 2006).
peripheral blood and in the bone marrow is also observed
Int. J. Mol. Med. Adv. Sci., 3 (4): 138-144, 2007
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The blast lineage is then determined by means of Phase 2: This step aims to prolong the complete
cytochemical stains as shown in Fig. 8. 
Analysis of the Myeloid antigens is also useful.
These include CD13, CD33, c-kit, CD14, CD64 (the latter 2
are monocytic markers) glycophorin A (an erythroid
marker) and CD41 (a megakaryocytic marker) (Estey et al.,
2006).
PATHOPHYSIOLOGY
Inversions in chromosome 16 lead to a genetic
variation in enzymes that detoxifies benzene and other
carcinogens such as the NADPH quinine oxidoreductase
1 (NQO1). A single 609C÷T substitution in NQO1,
decreases NQO1 activity and if the two alleles are mutant,
the enzyme activity is abolished.
It was found that the AML blasts are derived from
normal myeloblasts which have been affected by two
types of genetic damage.
Class 1: Activation of cell-surface receptors, such as
RAS,  or  receptor  tyrosine  kinases,  such  as  FLT3 and
c-KIT. This give the myeloblast a survival and
proliferative advantage through the activation of various
downstream pathways. This thus leads to clonal
expansion of the affected haemopoietic progentitors.
Studies performed on mice have demonstrated the fact
that abnormalities in RAS, FLT3, or c-KIT by themselves
produce only a myeloproliferative disorder and not AML
(Estey et al., 2006). 
Class 2: This is caused by the over expression of HOX
genes or formation of fusion genes (resulting from the
t(8;21) or inv(16) abnormalities) which block the myeloid
differentiation. These aberrations alone didn’t result in
AML in mice. But it has been proved that AML might
develop only when both classes of lesion are present
(Estey et al., 2006).
Various tumour suppressor genes were found to be
silenced in AML by permanent hypermethylation.
Studies  have  shown  that  the  most  common
somatic gene mutations in AML are in the nucleophosmin
gene, NPM1. It causes cytoplasmic and not nuclear
localisation  of  the  protein.  NRAS  or  KRAS  mutations
are less common and occur in about 18% of patients
(Estey et al., 2006).
Treatment: Usually the treatment consists of two phases.
Phase 1: This step attempts to produce a complete
remission i.e., a marrow with <5% blasts, a neutrophil
count >1000 and a platelet count > 100,000. This is the
only response that leads to a cure thus leading to an
increased survival rate.
remission that has commenced in Phase 1 (Estey et al.,
2006). 
Several drugs have been developed which target
target FLT3 aberrations and the RAS signalling pathway.
Besides this, hypomethylating agents, such as decitabine
and histone deacetylase inhibitors, such as valproic acid
might allow the transcription of genes silenced in AML.
Generally AML treatment consists of a combination of an
anthracycline line (e.g., daunorubicin and cytarabine).
Cytarabine is given by continuous intravenous fusion
daily for 7 days together with daunorubicin which is also
given daily for 3 days. Fifty to eighty percent of AML
patients might achieve complete remission (Estey et al.,
2006).
Additional chemotherapy must be administered to
cure  AML  in  postremission  patients.  If  not,  the
median  disease-free survival will not exceed four months
(Jabbour et  al.,  2006; Estey et al., 2006). If several
courses of induction therapy are given (also known as
consolidation therapy), there is a 40-50% chance of
survival at 4 years (Estey et al., 2006).
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